- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Bayer opens AI-enabled drug discovery center in UK | ||
| Mo | In a U-turn, ICER takes more positive view of AbbVie's Rinvoq | ||
| Mo | Roche's MabThera beats incumbent drug in pemphigus vulgaris phase 3 | ||
| Mo | FDA approves Lilly's migraine drug Reyvow | ||
| Mo | The 'blueprint' for MSL success is changing | ||
| Fr | Increased discount leads NICE to reverse positon on Clovis cancer drug | ||
| Fr | Report finds 'startling' lack of progress of antibiotic R&D agenda | ||
| Fr | Gilead builds case for Xeljanz rival filgotinib as it preps US filing | ||
| Fr | AbbVie calls time on Reata alliance, claims $330m payback | ||
| Fr | Rare diseases: redefining medical communications | ||
| Do | UCB gets bigger in rare diseases with $2.1bn purchase of Ra Pharma | ||
| Do | Daiichi starts challenging Astellas for Japanese AML market | ||
| Do | Novo Nordisk, bluebird team up to develop haemophilia A therapies | ||
| Do | Shionogi trumpets pneumonia data for new antibiotic cefiderocol | ||
| Do | Cooking up a co-creation feast - beyond vanilla | ||
| Mi | PMLiVE launches its inaugural T40 | ||
| Mi | Scottish government readies ports to mitigate Brexit supply disruptions | ||
| Mi | GSK forms cell therapy R&D pact with star-studded biotech | ||
| Mi | Merck seeks partner for disease-modifying osteoarthritis drug | ||
| Mi | J&J hit by $8bn judgment for man claiming breast growth due to Risperdal | ||
| 08.10. | ONEHealth bolstered by Bartlett Davis acquisition | ||
| 08.10. | New hires at Ashfield, Hamell and Springer Healthcare | ||
| 08.10. | Changing direction: adapting to a rapidly-evolving environment | ||
| 08.10. | SMC approves Yescarta and Keytruda, rejects Perjeta | ||
| 08.10. | Novartis bags US okay for Lucentis follow-up Beovu in wet AMD |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
